Summary Maspin, which belongs to the serine protease inhibitor (serpin) superfamily, has been proposed as a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis. In the present study, we examined the effects of 5-Aza-2'-deoxycytidine (5-Aza-dC), a demethylating agent, and FR901228, a histone deacetylase (HDAC) inhibitor, on maspin expression in oral cancer cell lines. The expression levels of maspin mRNA were divided into two groups, which was the maspin low-expressed and high-expressed cell lines in the 12 oral cancer cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines. Moreover, the methylation status was not altered after 5Aza-dC treatment. However, the transcription of the maspin gene was clearly increased following 5Aza-dC treatment in a number of oral cancer cell lines. These results imply that an action of 5Aza-dC is separate from induction of promoter demethylation. Treatment with FR901228 resulted in a time-dependent stimulation of the re-expression of maspin mRNA as early as 4 hours after treatment in the maspin downregulated cells. The re-expression of the maspin gene may contribute to the recuperation of biological functions linked to FR901228 such as an inhibitory effect on tumor angiogenesis and cell invasion. These results indicate that maspin and its target genes may be excellent leads for future studies on the potential benefits of FR901228, a histone deacetylase inhibitor, in cancer therapy.
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Introduction
Maspin is a Mr 42000 protein that belongs to the serine protease inhibitor (serpin) superfamily and is expressed in the epithelial cells of the airway, breast, skin, and prostate, but not in skin fibroblasts, lymphocytes, bone marrow, or the heart or kidneys [1, 2] . It is known to be a potent tumor suppressor that inhibits cell motility, invasion, angiogenesis, and metastasis [3] [4] [5] [6] [7] [8] .
Accumulative evidence demonstrates that maspin inhibits the progression of prostate and breast tumors at the late stages of invasion and metastasis [1, 7, [9] [10] [11] [12] . In several mammary carcinoma cell lines, maspin is undetectable or is expressed at very low levels [1] . A loss of maspin expression correlates with increased metastatic potential in breast cancer and other human tumors.
Maspin-transfected tumor cells tend to have less necrosis, mitogenesis, and neovascularization, which is associated with better prognosis and lower invasiveness [1, 9, 10, 13] . Domann et al. [14] and Futscher et al. [2] have shown that the silencing of maspin gene expression is inversely correlated with methylation of the promoter. Although the maspin gene is a potential clinical targeted invention, the regulating mechanism remains to be elucidated. Domann et al. [14] have shown that 5-Aza-2'-deoxycytidine (5-Aza-dC), known to be a demethylating agent, causes maspin mRNA levels to recover and suggests that methylation at CpGs, located in the maspin promoter, is the only impediment to maspin expression in a nonexpressing tissue. The maspin proximal promoter harbors many CpGs. Domann's study offers an intriguing theory of epigenetic silencing of the maspin gene.
Among the new classes of chemotherapeutic agents, histone deacetylase (HDAC) inhibitors have aroused considerable interest in the pursuit of improved anticancer agents. HDAC inhibitors increase or decrease the transcriptional levels of genes by causing hyperacetylation of histone, 4 which is considered to be a key mechanism for regulating transcription. Various HDAC inhibitors such as sodium butyrate (SB), trichostatin A (TSA), and trapoxin are known to inhibit histone deacetylase activities. FR901288, a novel cyclic peptide inhibitor of HDAC, is isolated from a fermentation broth of Chromobacterium violaceum. FR901228 has a stronger cytotoxic activity than TSA, although only a limited number of genes involved are known to increase or decrease their transcriptional levels followed by hyperacetylation of histone.
In the present study, we examined the regulatory effects of 5-Aza-dC and FR901228 on maspin in favor of its epigenetic regulation through a process such as histone acetylation and promoter methylation in oral cancer cell. (Tohoku University, Sendai, Japan). They were maintained in Dulbecco's modified Eagle's medium (DMEM) (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS, HyClone Laboratories, Inc., Logan, UT, USA), 100 units/ml penicillin (Meiji Seika Kaisha, Ltd., Tokyo, Japan) and 100 µg/ml streptomycin (Meiji Seika Kaisha) in a CO2 incubator (Sanyo Electric Co., Ltd., Osaka, Japan) with 95% air plus 5% CO2 at 37℃.
Chemicals
5-Aza-dC (Sigma Chemical Co., St Louis, MO, USA) and FR901288 (Fujisawa Pharmaceutical Company, Osaka, Japan) diluted in distilled water were added to the DMEM to the final concentrations indicated for each treatment.
5-Aza-dC treatment
Stock solutions of 5-Aza-dC were prepared by dissolving the drug at a 10 mM concentration in 6 distilled water no more than 2 h prior to use in the experiment. Final concentrations were obtained by diluting the stock solution directly into the tissue culture medium. Cells were incubated for 7 days with several different concentrations of 5-Aza-dC ranging from 4.4 to 22 µM.
FR901228 treatment
First, 1 × 10 5 cells were seeded in 5 ml MDEM in a petri dish (60 mm in diameter). At 7 days after seeding, the medium was changed to one containing FR901228, and the dish was incubated in a CO 2 incubator with 95% air plus 5% CO2 at 37℃ for an adequate number of hours.
DNA isolation and bisulfite modification
DNA was isolated by the standard method. Bisulfite treatment was carried out using the CpGenome DNA Modification Kit (Intergen Company, Manhattanville Road, NY) according to the instructions supplied. After bisulfite treatment, the DNA was resuspended in Tris EDTA (pH 7.5).
Bisulfite sequencing
The maspin promoter [15] was amplified from the bisulfite-modified DNA by PCR using primers specific to the bisulfite-modified sequence of the maspin promoter. The amplifications were Futscher. Amplified DNA was ligated into the TA topo cloning vector (Invitrogen, Corp., Carlsbad, CA) and transformed into E.coli, Topo 10; at least 5 clones of each fragment were sequenced using a Big Dye terminator sequencing kit (Perkin Elmer, Branchburg, NJ).
RNA isolation and RT-PCR
Extraction of total cellular RNA was carried out using Trizol reagent (Invitrogen Corp., 
Expression of maspin mRNA in oral cancer cell lines
The expression levels of maspin mRNA in 12 oral cancer cell lines were examined by RT-PCR. The gels clearly showed that the Hep2, SAS, KB, and HO-1-u-1 cell lines contained only trace amounts of maspin mRNA (Fig. 1) . The other cell lines produced uniformly large amounts of the maspin mRNA, as indicated by the very dense bands that appear in the relevant lanes ( Fig.   1 ).
Methylation map of the CpG island in the 5' region of the maspin gene CpGs.
We analyzed the methylation map of the CpG island in the promoter of the maspin gene in the three low-expressed cell lines (Hep2, SAS, KB). The maspin promoter contains only a few methylated CpG sites in the maspin low-expressed lines (Fig. 2, upper) .
Effects of 5-Aza-dC treatment on the expression and CpG methylation of the maspin gene
To test whether the maspin gene expression was suppressed by hypermethylation of its promoter, we exposed 5-Aza-dC, an inhibitor that prevents methylation of newly synthesized DNA, to three maspin downregulated cell lines (Hep2, KB, and SAS) and two maspin-expressed cell lines (HSC4 and HSC3). Our results clearly show that the five cell lines regained their ability to produce high levels of maspin mRNA following exposure to graded doses of 5-Aza-dC (Fig. 3) .
We also analyzed the methylation map in the promoter of the maspin after 5-Aza-dC treatment in 10 the three low-expressed cell lines (Hep2, SAS, and KB). After incubation with 4.4 µM 5-Aza-dC in a flask for 7 days, extracted DNA was bisulfited and sequenced as described in the Materials and Methods section. The methylation status was not altered after 5Aza-dC treatment (Fig. 2 lower) .
Effects of FR901228 treatment on maspin transcription
Three maspin downregulated cell lines that express low levels of maspin mRNA (Hep2, SAS, and KB) were incubated with FR901228 at a concentration of 0.5 or 1.0 μM. Two maspin-expressed cell lines (HSC4 and HSC3) were also analyzed as controls. Maspin expression was induced after 4-16 h of treatment with FR901228 in the maspin downregulated cell lines, while maspin transcriptional levels were not altered after treatment with FR901228 in the maspin-expressed cell lines (Fig. 4a) . As a negative control, human breast cancer cell line MCF-7, one of the maspin-negative lines, was incubated with FR901228. Its maspin expression was also induced in a time-dependent manner in MCF-7 (Fig. 4b) .
Discussion
The expression levels of maspin mRNA were divided into two groups, which was the maspin low-expressed and high-expressed cell lines in the 12 oral cancer cell lines. We first decided to examine the methylation status of the CpG island, one of the well-studied sites of epigenetic regulation in the maspin promoter region in the maspin low-expressed cell lines. The maspin promoter contained only a few methylated CpG sites in the maspin low-expressed cell lines.
Moreover, the methylation status was not altered after 5Aza-dC treatment. However, transcription of the maspin gene was clearly increased following 5Aza-dC treatment in a number of oral cancer cell lines. These results imply that the action of 5Aza-dC is separate from the induction of promoter demethylation. It is possible that 5Aza-dC disrupts complexes between DNA methyltransferases and histone-modifying proteins [18, 19] . Kondo et al. [20] have reported that 5Aza-dC dramatically decreases histone H3 Lys-9 methylation, slightly increases Lys-9 acetylation, and moderately increases histone H3 Lys-4 methylation and reactivated gene expression. These findings could explain the previously reported 5Aza-dC induced activation of the un-methylated gene [21, 22] and could also explain the maspin activation in our results.
HDAC inhibitors are known to modulate transcription and exert antiproliferative effects on cancer cells. Only a few target genes whose expression is upregulated in response to HDAC inhibitor-mediated growth arrest have been identified, e.g., the cyclin-dependent kinase inhibitors p21/WAF1 [23] [24] [25] , c-myc [26, 27] , and the anti-apoptotic bcl-2 gene [28, 29] . Among the latest reports, Butler et al. have found that Suberoylanilide hydroxamic acid (SAHA), one of the HDAC inhibitors, induces expression of the thioredoxin-binding protein-2 (TBP-2) gene in LNCaP prostate cells [30] . However, the gene responsible for inhibition of the proliferation and induction of cell differentiation or death by HDAC inhibitors remains elusive.
In the present study, we found that transcription of the maspin gene, whose expression has been implicated in apoptosis pathways as another possible candidate gene, is clearly increased following Additionally, our data suggest that maspin re-expressed by FR901228 can be an inhibitory regulator of natural tumor growth through its influence on neovascularization because the tumor suppressor activity of maspin may depend primarily on the inhibition of angiogenesis. Zhang et al. [10] have previously reported that maspin blocks the growth of human prostate tumor cells and dramatically reduces the density of tumor-associated microvessels in a xenograft mouse model.
In the present study, FR901228 was found to induce the gene expression of angiogenic-inhibitor maspin. Supporting our idea, specific HDAC inhibitors have been shown to inhibit angiogenesis [31, 32] , although little has been known about the mechanism of HDAC inhibitor in anti-angiogenesis until now. HDAC inhibitor should undergo further examination not only as an anti-angiogenesis agent, but also regarding its role in maspin re-expression to explore its potential as a possible biomarker for relapse risk in cancer therapy, as alterations in maspin expression are known to play an important role in oral tumorigenesis. In oral squamous cell carcinoma, high levels of maspin expression are associated with the absence of lymph node metastasis and with 13 better rates of overall survival [33] .
In conclusion, our research may provide a first suggestion of FR901228-dependent regulation of maspin in oral cancer. Maspin upregulation by FR901228 may be of critical importance in clinical treatment for cancer, and may contribute to the future development of treatment for human oral cancer. 
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